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1  | INTRODUCTION
According	 to	 the	 updated	 Sapporo	 criteria,	 the	 diagnosis	 of	 an-
tiphospholipid	syndrome	 (APS)	 implies	vascular	 thrombosis	and/or	
pregnancy	morbidity	and	at	 least	1	of	the	3	antiphospholipid	anti-
bodies	 (aPLs)	 (ie,	 lupus	 anticoagulant	 [LAC],	 anticardiolipin	 [aCL]
immunoglobulin	 (Ig)	 G/IgM	 antibodies	 and	 anti-β2	 glycoprotein	 I	
[aβ2GPI]	 IgG/IgM	 antibodies).1	 The	 “classical”	 clinical	 characteris-














technologies	 such	 as	 chemiluminescent	 and	 fluorescence	 enzyme	





on	 Lupus	 Anticoagulant/Antiphospholipid	 Antibodies	 (SSC-aPL)	 of	












To	 study	 cutoff	 establishment	 in	 clinical	 laboratories,	 we	 pre-
pared	 a	 questionnaire	 sent	 to	 SSC-aPL	members	 and	 participants	
of	 the	 Lupus	 Anticoagulant/Antiphospholipid	 Antibodies	 Program	
of	the	ECAT	(External	Quality	Control	for	Assays	and	Tests)	(ECAT	
Foundation,	Voorschoten,	The	Netherlands).	 Subsequently,	we	 set	
up	 a	 study	 to	 further	 investigate	 the	extent	of	 differences	 in	 cut-
off	values	determined	by	different	methods	of	calculation.	A	patient	
population	was	used	to	assess	the	impact	of	different	cutoff	values	
on	 the	analytical	 and	clinical	 performance	of	4	 commercial	 assays	
detecting	aPL.
2  | MATERIALS AND METHODS


















2.3 | Selection of patient groups
Patients	with	APS,	patients	with	non-APS	disease,	and	healthy	con-






1.	 Group	 A	 consisted	 of	 patients	 with	 thrombotic	 APS	 according	
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24%	 had	 arterial	 thrombosis,	 67%	 had	 venous	 thrombosis,	 and	
10%	 had	 thrombosis	 in	 both	 vascular	 beds.	 Numbers	 in	 each	






out	 thromboembolic	 or	 pregnancy	 complications.	 Numbers	 in	
each	center	were	as	follows:	Ghent,	n	=	97;	Krakow,	n	=	41.













1.	 The	 HemosIL	 AcuStar	 antiphospholipid	 assay	 (Werfen/
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bias.	P	 values	 associated	with	 odds	 ratios	were	 calculated	 by	 Fisher's	
exact	test.	A	P	<	0.05	was	considered	to	be	statistically	significant.
All	 statistical	 analyses	were	performed	using	Analyse-it	 4.81.1	
for	Microsoft	Excel	(Analyse-it	Software,	Leeds,	UK),	MedCalc	17.5.5	
(MedCalc	 Software,	 Ostend,	 Belgium),	 and	 DATAPLOT	 software	
package	 6/2013	 (National	 Institute	 of	 Standards	 and	 Technology,	
Gaithersburg,	MD).
3  | RESULTS




of	 the	 responses	 originated	 from	 Europe,	 17.0%	 from	 the	 United	
States,	11.4%	from	Asia,	7.9%	from	South	America,	and	2.3%	from	
Australia.	Over	85%	of	the	participating	laboratories	performed	all	
F I G U R E  1  Results	of	the	questionnaire.	(A)	Which	statistical	method	do	you	use?	(B)	Which	method	do	you	use	to	identify	outliers?	IQR,	
interquartile	range;	SD,	standard	deviation
Parametric method without data
transformation, mean + 2 SD
(A)
(B)
Parametric method without data
transformation, mean + 3 SD
Parametric method after data
transformation to achieve
normality, mean + 2 SD
Nonparametric method: right-
sided percentile estimation after
data transformation to achieve
normality
I don’t check for outliers
Reed (modified Dixon)
Tukey (larger than upper
quartile plus 1.5 times IQR)
Tukey (larger than upper
quartile plus 2.2 times IQR)
Tukey (larger than upper
quartile plus 3 times IQR)
Visually
Nonparametric method: right-
sided percentile estimation 
without data transformation





















(mean	+	2SD)	 in	19.4%,	without	data	transformation	 (mean	+	3SD)	 in	
13.9%,	and	after	data	transformation	to	achieve	normality	(mean	+	2SD)	














































outliers.	 Excluding	 these	 subjects	 from	 the	 calculations	 lowered	





percentile	 cutoffs	were	 lower	 than	 the	manufacturers’	 cutoffs.	 In	
contrast,	 the	99th	percentile	cutoffs	were	equal	 to	or	higher	 than	
the	manufacturers’	cutoffs.
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99th P method A
99th P method A, Reed
99th P method A, TM
99th P method B
99th P method B, Reed
99th P method B, TM
95th P method A
95th P method A, Reed
95th P method A, TM
95th P method B
95th P method B, Reed
95th P method B, TM
Manufacturer’s cutoff
AcuStar aβ2GPI IgM















































































































EliA aCL IgM EliA aβ2GPI IgG EliA aCL IgG































QUANTA Lite aCL IgM QUANTA Lite aβ2GPI IgG QUANTA Lite aCL IgG
(A) (B) (C) (D)
(E) (F) (G) (H)
(I) (J) (K) (L)
(M) (N) (O) (P)
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With	all	99th	percentile	 cutoffs	 investigated	 (based	on	120	
normal	 controls),	 kappa	 ranged	 from	 0.52	 to	 0.90	 for	 aβ2GPI	
IgM;	from	0.22	to	0.73	for	aCL	IgM;	from	0.71	to	0.97	for	aβ2GPI	
IgG;	and	from	0.63	to	0.95	for	aCL	IgG.	With	all	95th	percentile	

























































































































































































































































































































































































95% CI 95% CI YI (%)Spec (%)
BioPlex
99th P method A, Reed
99th P method A, TM
99th P method B, no outlier
99th P method B, Reed
99th P method B, TM
95th P method A, Reed
95th P method A, TM
95th P method B, no outlier
95th P method A, no outlier
95th P method B, Reed
95th P method B, TM
99th P method A, no outlier
99th P method A, Reed
99th P method A, TM
99th P method B, no outlier
99th P method B, Reed
99th P method B, TM
95th P method A, Reed
95th P method A, TM
95th P method B, no outlier
95th P method A, no outlier
95th P method B, Reed
95th P method B, TM
Manufacturer’s cutoff
EliA
99th P method A, no outlier
99th P method A, Reed
99th P method A, TM
99th P method B, no outlier
99th P method B, Reed
99th P method B, TM
95th P method A, Reed
95th P method A, TM
95th P method B, no outlier
95th P method A, no outlier
95th P method B, Reed
95th P method B, TM
Manufacturer’s cutoff
QUANTA Lite
99th P method A, no outlier
99th P method A, Reed
99th P method A, TM
99th P method B, no outlier
99th P method B, Reed
99th P method B, TM
95th P method A, Reed
95th P method A, TM
95th P method B, no outlier
95th P method A, no outlier
95th P method B, Reed
95th P method B, TM
0 5 10 15
OR
(A)
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3.4 | Diagnostic performances
We	compared	the	results	for	aCL	and	aβ2GPI	antibodies	obtained	
with	HemosIL	AcuStar,	 BioPlex,	 EliA,	 and	QUANTA	 Lite	with	 the	
presence	 of	 clinical	 features	 of	 the	 patients.	 Odds	 ratios,	 sensi-
tivities,	 specificities,	 and	Youden	 indexes	 are	 shown	 in	 Tables	 S3	
through	S6.	A	summary	of	these	data	is	shown	in	Figure	4,	show-
ing	 the	 test	 statistics	when	at	 least	1	of	 the	 aPL	panel	 tests	was	
positive.
All	 aCL	 and	 aβ2GPI	 IgM	 assays	 showed	 a	 poor	 relationship	
with	thrombotic	events.	In	contrast,	IgG	positivity	was	found	to	be	
strongly	associated	with	thrombosis.	With	increasing	aPL	titers	(eg,	

















































































































































































































































































































































































95% CI 95% CI YI (%)Spec (%)
BioPlex
99th P method A, Reed
99th P method A, TM
99th P method B, no outlier
99th P method B, Reed
99th P method B, TM
95th P method A, Reed
95th P method A, TM
95th P method B, no outlier
95th P method A, no outlier
95th P method B, Reed
95th P method B, TM
99th P method A, no outlier
99th P method A, Reed
99th P method A, TM
99th P method B, no outlier
99th P method B, Reed
99th P method B, TM
95th P method A, Reed
95th P method A, TM
95th P method B, no outlier
95th P method A, no outlier
95th P method B, Reed
95th P method B, TM
Manufacturer’s cutoff
EliA
99th P method A, no outlier
99th P method A, Reed
99th P method A, TM
99th P method B, no outlier
99th P method B, Reed
99th P method B, TM
95th P method A, Reed
95th P method A, TM
95th P method B, no outlier
95th P method A, no outlier
95th P method B, Reed
95th P method B, TM
Manufacturer’s cutoff
QUANTA Lite
99th P method A, no outlier
99th P method A, Reed
99th P method A, TM
99th P method B, no outlier
99th P method B, Reed
99th P method B, TM
95th P method A, Reed
95th P method A, TM
95th P method B, no outlier
95th P method A, no outlier
95th P method B, Reed
95th P method B, TM
0 5 10 15
OR
(B)
F I G U R E  4   (Continued)
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from	the	95th	to	the	99th	percentile),	a	trend	of	an	increased	risk	for	
thrombosis	was	obtained.









mal	 controls),	 the	 sensitivity	 and	 specificity	 varied	 from	 8.7%	 to	
19.4%	and	85.7%	to	95.0%	for	aβ2GPI	IgM,	from	8.3%	to	27.8%	and	





With	 all	 99th	 percentile	 cutoffs	 investigated	 (based	 on	 120	
normal	 controls),	 the	 sensitivity	 and	 specificity	 varied	 from	 4.0%	
to	13.9%	and	91.3%	to	97.8%	for	aβ2GPI	IgM,	from	0.8%	to	15.9%	
and	88.8%	to	99.1%	for	aCL	IgM,	from	14.3%	to	23.0%	and	95.3%	
to	99.7%	 for	 aβ2GPI	 IgG,	 and	 from	10.7%	 to	23.0%	and	95.0%	 to	




calculated on outlier deleted data.
4  | DISCUSSION
Defining	cutoff	 reference	values	 for	 aPL-solid	phase	assays	 is	one	
of	 the	 factors	 that	determines	 the	classification	of	a	patient	as	an	
APS	patient	or	not.	The	 interpretation	of	 results	 is	determined	by	
the	cutoff	values	and	plays	a	major	role	in	classifying	a	sample	as	aPL	






tion	 curves,	 and	 results	of	 aCL	and	aβ2GPI	 tests	 are	expressed	 in	
units	on	a	continuous	scale.	Each	test	result	above	the	cutoff	value	
calculated	 as	 higher	 than	 the	 99th	 percentile	 should	 be	 regarded	
as	positive,	according	to	the	SSC	recommendations	for	solid-phase	
assays.6
SSC-aPL	 recommendations	 were	 published	 in	 2014,	 providing	
detailed	information	on	the	execution	of	solid-phase	assays	for	aPL,	
including	 recommendations	 on	 the	 calculation	 of	 cutoff	 values.6 
The	questionnaire	revealed	that	 in	daily	practice,	84.5%	(109/129)	
of	 the	 laboratories	 apply	 cutoff	 values	 according	 to	 the	 recom-
mendations,	either	by	calculating	in-house	cutoffs	(48.6%;	53/109)	
or	 by	 transference	 of	 the	 manufacturer's	 cutoff	 (51.4%;	 56/109).	






ues	 for	 aCL	and	aβ2GPI	antibodies	 analyzed	on	4	different	plat-
forms	and	to	define	the	optimal	method	of	calculation	by	analyzing	
the	 diagnostic	 performance	 in	 a	 case-control	 design.	 Previous	
studies	defining	optimal	aPL	cutoffs	focused	on	the	optimal	sep-
aration	of	 cases	and	controls.9,14	However,	 this	approach	has	 in-
herent	weaknesses.15,16	Instead,	we	propose	a	different	approach	
that	 takes	 advantage	 of	 the	 Youden	 index	 to	 select	 the	 optimal	
cutoff	value.
The	 aPL	 results	 from	 the	 normal	 controls	were	 not	 normally	








different	 values	 were	 obtained	 when	 using	 data	 from	 200	 nor-
mal	 controls,	 pointing	 to	 an	 inherent	degree	of	uncertainty.	The	


















assumption	 that	 samples	 from	 normal	 donors	 are	 negative	 for	 all	
aPL.	However,	given	the	high	titer	of	aPL,	the	subjects	classified	as	
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The	 sample	 size	 requirement	 causes	 a	 problem	 concern-
ing	 the	 feasibility	 of	 local	 laboratories	 to	 establish	 cutoff	 values.	
Verification	 of	 the	 manufacturer's	 cutoff	 using	 a	 small	 number	
may	be	an	alternative	when	local	cutoff	calculation	is	not	feasible.6 
However,	this	would	assume	that	manufacturers’	cutoffs	are	estab-
lished	 by	 appropriate	 statistical	models	 using	 a	 sufficiently	 large	
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